Trial Search Results

Modified Dakin's Solution in Reducing Radiation-Induced Dermatitis in Patients With Head and Neck Cancer Undergoing Radiation Therapy

This randomized phase III trial studies how well modified Dakin's solution works in reducing radiation-induced dermatitis, a common skin reaction to radiation therapy, in patients with head and neck cancer undergoing radiation therapy. Modified Dakin's solution may reduce inflammation in the body, which may prevent or reduce dermatitis after radiation therapy.

Stanford is currently accepting patients for this trial.

Lead Sponsor:

Stanford University

Collaborator: National Cancer Institute (NCI)


  • Drug: Dakin's solution
  • Other: Placebo
  • Other: Questionnaire Administration


Phase 3


Inclusion Criteria:

   - Patients with head and neck cancer who plan to undergo radiation therapy to the head
   and neck region

   - Patients must be at least 18 years of age

   - Patients must be able to understand and the willingness to sign a written informed
   consent document.

Exclusion Criteria:

   - Patients with prior radiation therapy to the head and neck region or prior
   chemotherapy for head and neck cancer (induction chemotherapy NOT excluded)

   - Patients whose physician-approved radiation treatment plan indicates a maximum
   prescription dose of less than 45 Gy

   - Patients with scleroderma or discoid lupus

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study


Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Amanda Simmons